medigraphic.com

2006, Number 6

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2006; 44 (6)

Quality Life in Climateric Patients With and Without Hormonal Replacement Therapy?

Téxon FO, Márquez CFG

Language: Spanish
References: 18
Page: 541-546
PDF size: 97.67 Kb.


ABSTRACT

Objective: to compare quality of life in climacterical women with and without hormone repla-cement therapy.
Material and methods: a cross-sectional analytical study was carried out in the Family Medicine Unit number 61 in Veracruz, Veracruz. There were chosen 102 women between 40 and 60 years old. There were two groups: the first one with 51 patients with hormone replacement therapy during the last year; the second one with 51 patients who are not in hormone replacement therapy. Coop/wonca charts were used to measure quality of life. A complementary questionnaire related to climacteric period and menopause was answered by both groups. Statistical test with c2 was carried out.
Results: health condition and satisfactory sexual life were improved in patients with hormone replacement therapy (30 versus 19, p = 0.007; and 40 cases versus 30, p = 0.04, respectively). No significantly differences were found in six from seven coop/wonca charts.
Conclusions: there were no impact results in climacteric and menopause women. However, a better health condition and satisfactory sexual life were observed in patients with hormonal replacement therapy.


REFERENCES

  1. 1. Chávez-Ayala R, Andrade-Palos P, Rivera-Rivera L. Validación de un cuestionario para la medición de las creencias sobre el climaterio. Salud Publica Mex 2002;44:385-391.

  2. 2. Velarde-Jurado E, Ávila-Figueroa C. Methods for the quality of life assessment. Salud Publica Mex 2002; 44:1-15.

  3. 3. Lizan R, Reig A. Adaptación transcultural de una medida de la calidad de vida relacionada con la salud: la versión española de las viñetas coop-wonca. Aten Primaria 2002;29:128-138.

  4. 4. Balash J, Terapia hormonal sustitutiva como pre-vención en la posmenopausia: ¿fin de la contro-versia? Med Clin (Barc) 2002;119:416-417.

  5. 5. Siddiqui NI, Rahman S, Mia AR, Shamsuzzaman AK. Evaluation of hormone replacement therapy. Mymensingh Med J 2005;14(2):212-218.

  6. 6. Hlatky M, Boothroyd D, Vittinghoff E, Sharp P, Whooley M. Quality of life and depressive symptoms in postmenopausal women after recovering hormone therapy: results from the Heart and Estrogen/Progestin Replacement Study (HERS) Trial. JAMA 2002;287:591-597.

  7. 7. Zweifel J, O’Brien W. A meta-analysis of the effect of hormone replacement therapy upon depressed mood. Psychoneuroendocrinology 1997;22:655.

  8. 8. Hays J, Ockene JK, Brunner RL, Kotchen JM, Manson JE, Patterson RE, Aragaki AK, Shumaker SA, et al. (The Womens’s Health Initiative Investigators). Effects of estrogen plus progestin on health-related quality of life. Obstet Gynecol Surv 2003;58(10): 671-672.

  9. 9. Parra M. Menopausia en Chile y Latinoamérica. En: González O, Arteaga E, Contreras P. Menopausia y patologías asociadas. Santiago de Chile: Ediciones Sociedad Chilena de Climaterio; 1998. p. 85-91.

  10. Balash J, González-Merlo J. Terapéutica hormonal sustitutiva, ¿la esperanza perdida? Prog Obstet Ginecol 2002;45:229-231.

  11. Hickey M, Davis SR, Sturdee DW. Treatment of menopausal symptoms: what shall we do now? Lancet 2005;366(9483):409-421.

  12. Barnabei VM, Cochrane BB, Aragaki AK, Nygaard I, Williams RS, McGover PG, Young RL, Wells EC, O’Sullivan MJ, Chen B, Schenken R, Johnson SR; Women’s Health Initiative Investigators. Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women’s Health Initiative. Obstet Gynecol 2005;105 (5 Pt 1):1063-1073.

  13. Hlatky M, Boothroyd D, Vittinghoff E, Sharp P, Whooley M. Quality-of-life and expressive symptoms in postmenopausal women after receiving hormone therapy: results from the Heart and Estrogen/Progestin Replacement Study (HERS) Trial. JAMA 2002;287:591-597.

  14. Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321-333.

  15. Beral V; Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362 (9390):1160.

  16. Bhavnani BR, Strickler RC. Menopausal hormone therapy. Obstet Gynaecol Can 2005;27(2):137-162.

  17. Modena MG, Sismondi P, Mueck AO, Kuttenn F, Lignieres B, Verhaeghe J, Foidart JM, Caufriez A, Genazzani AR; The TREAT. New evidence regarding hormone replacement therapies is urgently required transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits. Maturitas 2005;52(1):1-10.

  18. Lukaczer D, Darland G, Tripp M, Liska D, Lerman RH, Schiltz B, Bland JS. Clinical effects of a proprietary combination isoflavone nutritional supplement in menopausal women: a pilot trial. Altern Ther Health Med 2005;11(5):60-65.




2020     |     www.medigraphic.com